ReviewThrombosis journal2016
Management of venous thromboembolism: an update.
Review in Thrombosis journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05313620 (Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Safety and Effectiveness of Direct Oral Anticoagulants Versus Warfarin in Patients with Venous Thromboembolism using Real-World Data: A Systematic Review and Meta-Analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Pooled it
- Pooled it
- Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.The Korean journal of internal medicine · 2019Trial
- Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial.Clinical drug investigation · 2018Trial
- Venous Thromboembolism in Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2023Review
- The Auxiliary Role of Heparin in Bone Regeneration and its Application in Bone Substitute Materials.Frontiers in bioengineering and biotechnology · 2022Review
- Heritable Thrombophilia in Venous Thromboembolism in Northern Pakistan: A Cross-Sectional Study.Advances in hematology · 2021Article
- Venous thromboembolism in inflammatory bowel disease.World journal of gastroenterology · 2020Review
- Anticoagulants and Osteoporosis.International journal of molecular sciences · 2019Review
- Plasma contact factors as therapeutic targets.Blood reviews · 2018Review
- Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.Drug delivery and translational research · 2018Review
- Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.Journal of thrombosis and thrombolysis · 2018Article
- Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation.TH open : companion journal to thrombosis and haemostasis · 2018Article
- [The conspicuous leg].Der Internist · 2018Review
- Efficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism.Journal of thrombosis and thrombolysis · 2018Article
- Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis.Thrombosis journal · 2017Article
- Outpatient Treatment in Low-Risk Pulmonary Embolism Patients Receiving Direct Acting Oral Anticoagulants Is Associated With Cost Savings.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE), which constitutes pulmonary embolism and deep vein thrombosis, is a common disorder associated with significant morbidity and mortality. Landmark trials have shown that direct oral anticoagulants (DOACs) are as effective as conventional anticoagulation with vitamin K antagonists (VKA) in prevention of VTE recurrence and associated with less bleeding. This has paved the way for the recently published guidelines to change their recommendations in favor of DOACs in acute and long-term treatment of VTE in patients without cancer. The recommended treatment of VTE in cancer patients remains low-molecular-weight heparin. The initial management of pulmonary embolism (PE) should be directed based on established risk stratification scores. Thrombolysis is an available option for patients with hemodynamically significant PE. Recent data suggests that low-risk patients with acute PE can safely be treated as outpatients if home circumstances are adequate. There is lack of support for use of inferior vena cava filters in patients on anticoagulation. This review describes the acute, long-term, and extended treatment of VTE and recent evidence on the management of sub-segmental PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.